We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
-19.3%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$82.8M
AUM Growth
-$28.8M
(-26%)
Cap. Flow
-$2.79M
Cap. Flow
% of AUM
-3.37%
Top 10 Holdings %
Top 10 Hldgs %
36.35%
Holding
122
New
10
Increased
23
Reduced
52
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CareDx
CDNA
|
+$930K |
| 2 |
Gilead Sciences
GILD
|
+$732K |
| 3 |
BEAT
BioTelemetry, Inc.
BEAT
|
+$704K |
| 4 |
Alphatec Holdings
ATEC
|
+$579K |
| 5 |
Rockwell Medical
RMTI
|
+$577K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aflac
AFL
|
+$1.02M |
| 2 |
Microvision
MVIS
|
+$808K |
| 3 |
The Joint Corp
JYNT
|
+$802K |
| 4 |
CEMI
Chembio diagnostics, Inc.
CEMI
|
+$780K |
| 5 |
ANI Pharmaceuticals
ANIP
|
+$709K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.87% |
| 2 | Technology | 10.8% |
| 3 | Communication Services | 7.03% |
| 4 | Industrials | 5.89% |
| 5 | Consumer Staples | 4.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
AbbVie
ABBV
$435B
| $1.09M | 1.32% |
14,338
-200
| -1% | -$17K |
|
|
AKTS
27
DELISTED
Akoustis Technologies Inc
AKTS
| $1.07M | 1.29% |
199,150
-4,350
| -2% | -$30.5K |
|
28
Castle Biosciences
CSTL
$929M
| $1.01M | 1.22% |
33,850
+6,455
| +24% | +$195K |
|
29
Digital Turbine
APPS
$1.59B
| $1.01M | 1.22% |
233,550
-19,250
| -8% | -$119K |
|
30
Merck
MRK
$317B
| $986K | 1.19% |
13,430
+995
| +8% | +$78.2K |
|
31
Inuvo
INUV
$18M
| $950K | 1.15% |
401,872
+133,929
| +50% | +$374K |
|
32
Bristol-Myers Squibb
BMY
$130B
| $941K | 1.14% |
16,875
-300
| -2% | -$18.3K |
|
33
Target
TGT
$67.1B
| $909K | 1.1% |
9,779
-2,050
| -17% | -$228K |
|
34
Tactile Systems Technology
TCMD
$676M
| $854K | 1.03% |
21,267
-83
| -0.4% | -$4.45K |
|
35
Verizon
VZ
$193B
| $828K | 1% |
15,409
| – | – |
|
|
PFIE
36
DELISTED
Profire Energy, Inc
PFIE
| $827K | 1% |
1,049,489
+434,689
| +71% | +$530K |
|
37
LifeVantage
LFVN
$84M
| $822K | 0.99% |
79,810
| – | – |
|
38
3M
MMM
$93.9B
| $799K | 0.97% |
7,004
+2,691
| +62% | +$354K |
|
|
39
Gilead Sciences
GILD
$164B
| $792K | 0.96% |
+10,600
| New | +$732K |
|
|
HTGM
40
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
| $791K | 0.96% |
13,522
-517
| -4% | -$50.6K |
|
41
Ciena
CIEN
$57.9B
| $766K | 0.93% |
19,250
-1,000
| -5% | -$41K |
|
42
Advanced Micro Devices
AMD
$786B
| $730K | 0.88% |
16,050
-3,000
| -16% | -$145K |
|
43
CVS Health
CVS
$126B
| $698K | 0.84% |
11,769
-2,066
| -15% | -$138K |
|
|
QUMU
44
DELISTED
Qumu Corp.
QUMU
| $677K | 0.82% |
408,000
-19,000
| -4% | -$38.6K |
|
45
Standard BioTools
LAB
$307M
| $646K | 0.78% |
254,267
+30,684
| +14% | +$101K |
|
|
46
Alphatec Holdings
ATEC
$1.48B
| $644K | 0.78% |
186,750
+100,750
| +117% | +$579K |
|
47
Ooma
OOMA
$590M
| $631K | 0.76% |
52,850
-1,000
| -2% | -$12.6K |
|
48
BioLife Solutions
BLFS
$1.65B
| $610K | 0.74% |
64,250
-17,300
| -21% | -$238K |
|
49
Sensus Healthcare
SRTS
$48.4M
| $590K | 0.71% |
235,944
-1,242
| -0.5% | -$4.62K |
|
|
ATRS
50
DELISTED
Antares Pharma, Inc.
ATRS
| $548K | 0.66% |
232,166
-24,667
| -10% | -$83.9K |
|
Similar funds
PWP
BF
HWMG
WT
BAM
WLG
PA
STFP
Perkins Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Perkins Capital Management held 122 positions worth $82.8M, down 26% from $112M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Perkins Capital Management withdrew a net $2.79M in Q1 2020, closing 15 positions and reducing 52 holdings. Its most notable exit was Aflac, an estimated $1.02M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 63% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Perkins Capital Management opened a new position in Gilead Sciences worth $792K.
- Perkins Capital Management's largest Q1 2020 buy was Gilead Sciences: 10,600 shares worth $792K.
- Perkins Capital Management added most to CareDx in Q1 2020, an estimated $930K increase.
- Perkins Capital Management's biggest Q1 2020 reduction was Veritone, cutting an estimated $542K.
- Perkins Capital Management fully exited Aflac in Q1 2020, selling an estimated $1.02M.
- Perkins Capital Management's ten largest holdings make up 36% of its $82.8M portfolio in Q1 2020.
- Perkins Capital Management opened 10 new positions and closed 15 in Q1 2020.
- Perkins Capital Management's portfolio value fell 26% quarter-over-quarter to $82.8M.
Based on Perkins Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.